Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577833 | 0.86 | FAP (0.56) | DRD2DRD3BCHEKDM4EALDH1A1 | |
| SCHEMBL5577389 | 0.84 | CHRM3 (0.61) | DRD2DRD3BCHEDRD4KDM4E | |
| SCHEMBL5577377 | 0.82 | LMNA (0.53) | DRD2DRD3BCHEDRD4KLKB1 | |
| SCHEMBL5577914 | 0.81 | CHRM3 (0.59) | DRD2DRD3DRD4KDM4EALDH1A1 | |
| SCHEMBL31512419 | 0.80 | NSD2 (0.67) | NSD2KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5577624 | 0.80 | KMT2A (0.53) | DRD2DRD3DRD4KLKB1KLK1 | |
| SCHEMBL5577583 | 0.80 | CCR3 (0.55) | DRD4NSD2CCR3 | |
| SCHEMBL5577761 | 0.77 | CHRM3 (0.58) | KDM4EALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL5577821 | 0.76 | POLB (0.55) | DRD2DRD3BCHEDRD4KLKB1 | |
| SCHEMBL5577721 | 0.76 | ALDH1A1 (0.58) | DRD2DRD3DRD4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | DRD2 4468/4885DRD3 4080/4885BCHE 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.